Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.
Euro Surveill
; 27(38)2022 09.
Article
in English
| MEDLINE | ID: covidwho-2054865
ABSTRACT
Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95%â¯CI -38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization's decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Influenza Vaccines
/
Influenza, Human
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal subject:
Communicable Diseases
Year:
2022
Document Type:
Article
Affiliation country:
1560-7917.ES.2022.27.38.2200720
Similar
MEDLINE
...
LILACS
LIS